A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age
Conditions
Interventions
- BIOLOGICAL: Pn-MAPS30plus
- COMBINATION_PRODUCT: PCV20
Sponsor
GlaxoSmithKline